CR10295A - "formulacion de un anticuerpo monoclonal humano anti-igf-1r" - Google Patents

"formulacion de un anticuerpo monoclonal humano anti-igf-1r"

Info

Publication number
CR10295A
CR10295A CR10295A CR10295A CR10295A CR 10295 A CR10295 A CR 10295A CR 10295 A CR10295 A CR 10295A CR 10295 A CR10295 A CR 10295A CR 10295 A CR10295 A CR 10295A
Authority
CR
Costa Rica
Prior art keywords
igf
formulation
monoclonal antibody
human monoclonal
preparation
Prior art date
Application number
CR10295A
Other languages
English (en)
Spanish (es)
Inventor
Adelbert Grossmann
Hanns-Christian Mahler
Astrid Pappenberger
Oliver Boris Stauch
Jan Olaf Stracke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR10295A publication Critical patent/CR10295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CR10295A 2006-03-28 2008-09-17 "formulacion de un anticuerpo monoclonal humano anti-igf-1r" CR10295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
CR10295A true CR10295A (es) 2008-10-06

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10295A CR10295A (es) 2006-03-28 2008-09-17 "formulacion de un anticuerpo monoclonal humano anti-igf-1r"

Country Status (18)

Country Link
EP (1) EP1998806A1 (fr)
JP (1) JP2009531371A (fr)
KR (1) KR20080104160A (fr)
CN (1) CN101410137A (fr)
AR (1) AR060130A1 (fr)
AU (1) AU2007229554A1 (fr)
BR (1) BRPI0709229A2 (fr)
CA (1) CA2647111A1 (fr)
CL (1) CL2007000797A1 (fr)
CR (1) CR10295A (fr)
EC (1) ECSP088778A (fr)
IL (1) IL193904A0 (fr)
MA (1) MA30345B1 (fr)
MX (1) MX2008012295A (fr)
NO (1) NO20083895L (fr)
RU (1) RU2008142359A (fr)
TW (1) TW200815029A (fr)
WO (1) WO2007110339A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081477A1 (es) * 2006-12-11 2008-10-18 Hoffmann La Roche Formulacion liofilizada mab abeta
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
BRPI0809112A2 (pt) * 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
CN101687038A (zh) * 2007-07-10 2010-03-31 霍夫曼-拉罗奇有限公司 新型制剂
CA2706403A1 (fr) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Agregats d'immunoglobulines
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
WO2010069858A1 (fr) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011080209A2 (fr) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Nouvelle formation d'anticorps
WO2011147921A1 (fr) * 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
HUE039209T2 (hu) 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
CN102363040B (zh) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 用于粘膜组织的抗微生物肽制剂
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CN103505729B (zh) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3094648A1 (fr) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Variants de région fc présentant une liaison améliorée à la protéine a
EP3148568A4 (fr) * 2014-05-28 2018-01-17 Nono Inc. Formulation lyophilisée de tat-nr2b9c avec capteur d'acétylation
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
CA2985718A1 (fr) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps anti-recepteur de la transferrine avec une affinite adaptee
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
AU2017312785A1 (en) 2016-08-16 2019-01-24 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP4071469A3 (fr) 2016-10-25 2022-12-14 Regeneron Pharmaceuticals, Inc. Procédés et systèmes d'analyse de données de chromatographie
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
CA3073935A1 (fr) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Procedes de reduction de la formation de particules et compositions formees par ceux-ci
EA202190163A1 (ru) 2018-07-02 2021-03-30 Ридженерон Фармасьютикалз, Инк. Системы и способы получения полипептида из смеси
CN114324882B (zh) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
PE20020801A1 (es) * 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
KR100825156B1 (ko) * 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 변형된 인간 ｉｇｆ-ｉｒ 항체

Also Published As

Publication number Publication date
EP1998806A1 (fr) 2008-12-10
TW200815029A (en) 2008-04-01
WO2007110339A1 (fr) 2007-10-04
AR060130A1 (es) 2008-05-28
IL193904A0 (en) 2011-08-01
JP2009531371A (ja) 2009-09-03
RU2008142359A (ru) 2010-05-10
MA30345B1 (fr) 2009-04-01
KR20080104160A (ko) 2008-12-01
AU2007229554A1 (en) 2007-10-04
CA2647111A1 (fr) 2007-10-04
ECSP088778A (es) 2008-10-31
CN101410137A (zh) 2009-04-15
NO20083895L (no) 2008-10-24
MX2008012295A (es) 2008-10-09
CL2007000797A1 (es) 2008-01-25
BRPI0709229A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
CR10295A (es) "formulacion de un anticuerpo monoclonal humano anti-igf-1r"
ECSP10010295A (es) Formulacion de anticuerpo
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
AR057224A1 (es) Moleculas de anticuerpo que tienen especificidad para la il- 6 humana
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
ECSP077261A (es) Composición de anticuerpo her2
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
MY157661A (en) Bendamustine pharmaceutical compositions
CR10561A (es) Vacunas para malaria
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
PA8654701A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
HN2010000573A (es) Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)